MVRx is a leading medical technology company based in Silicon Valley that specializes in cardiovascular solutions. They have developed the groundbreaking ARTO System, an implantable transcatheter device specifically designed to treat Functional Mitral Regurgitation (FMR). This proprietary device is at the forefront of innovation in the field.

MVRx boasts a strong team of experts, including Samantha Greene, the President & Chief Executive Officer, with over 20 years of experience in the medical device and biotech industry, particularly in cardiovascular technology. Additionally, their Vice President of Operations, Pat Wu, has more than 20 years of experience in medical device R&D and operational management. David Rahdert, the Senior Director of Research & Development and Co-Founder, brings a wealth of knowledge with his 25-year background in engineering in the medical technology field.

MVRx is committed to delivering advanced solutions to improve the lives of patients with cardiovascular conditions. Their dedication to innovation and their top-notch team sets them apart in the industry. For more information about MVRx and their transformative technologies, visit their website or contact them directly at info@mvrxinc.

com